Currently, therapeutic strategies for renal anemia focus on correcting anemia itself through the use of erythropoiesis-stimulating agents, recombinant human EPO, and inhibitors of prolyl-hydroxylase-HIF, which are used primarily to increase EPO levels and stimulate erythropoiesis (Heras-Benito, 2023). This evidence concerns the gene EPO and anemia (phenotype).